U.S. Markets close in 25 mins

Idera Pharmaceuticals, Inc. (IDRA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.0900+0.0700 (+3.47%)
As of 3:34PM EDT. Market open.

Idera Pharmaceuticals, Inc.

505 Eagleview Boulevard
Suite 212
Exton, PA 19341
United States

Full Time Employees36

Key Executives

NameTitlePayExercisedYear Born
Mr. Vincent J. MilanoPres, CEO & Director952.08kN/A1964
Mr. John J. KirbySr. VP & CFO459.51kN/A1972
Mr. Bryant David LimSr. VP, Gen. Counsel & Corp. Sec.524.64kN/A1971
Mr. Robert Clayton FletcherSr. VP of Bus. Devel. & Strategic Planning591.08kN/A1963
Ms. Jill ConwellSr. VP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania.

Corporate Governance

Idera Pharmaceuticals, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.